APA (7th ed.) Citation

Morgan, C., Jin, X., Yu, X., De Rosa, S., Kublin, J., Metch, B., . . . Niaid, H. (2012). DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials. Retrovirology, 9(Suppl 2), 1. https://doi.org/10.1186/1742-4690-9-S2-P133

Chicago Style (17th ed.) Citation

Morgan, C., X. Jin, X. Yu, S. De Rosa, J. Kublin, B. Metch, M. Keefer, and H. Niaid. "DNA Plasmid HIV Vaccine Design, Number of Doses, Participant Gender, and Body Mass Index Affect T-cell Responses Across HIV Vaccine Clinical Trials." Retrovirology 9, no. Suppl 2 (2012): 1. https://doi.org/10.1186/1742-4690-9-S2-P133.

MLA (9th ed.) Citation

Morgan, C., et al. "DNA Plasmid HIV Vaccine Design, Number of Doses, Participant Gender, and Body Mass Index Affect T-cell Responses Across HIV Vaccine Clinical Trials." Retrovirology, vol. 9, no. Suppl 2, 2012, p. 1, https://doi.org/10.1186/1742-4690-9-S2-P133.